Change
Tools: Print  PDF Download Key Figures Comparison

Note 10 Property, plant and equipment


 

 

 

 

 

 

Download XLS

 

 

 

 

 

 

 

In € millions

Total

Buildings and land

Plant equipment and machinery

Other equipment

Construction in progress and prepayments on projects

Assets not used in the production process

1

Mainly Organon BioSciences.

2

Mainly ICI.

 

 

 

 

 

 

 

Balance at January 1, 2007

 

 

 

 

 

 

Cost of acquisition

9,179

2,671

5,176

896

276

160

Accumulated depreciation/impairment

(5,833)

(1,292)

(3,763)

(661)

(117)

 

 

 

 

 

 

 

Carrying value

3,346

1,379

1,413

235

276

43

 

 

 

 

 

 

 

Changes in carrying value

 

 

 

 

 

 

Acquisitions through business combinations

17

6

10

1

Divestments1

(1,194)

(586)

(297)

(96)

(175)

(40)

Capital expenditures

511

65

258

61

124

3

Transfer between categories

24

3

8

(38)

3

Depreciation

(407)

(80)

(264)

(60)

(3)

Impairment

(3)

(1)

(1)

(1)

Reversal of impairments

7

1

2

4

Changes in exchange rates

(74)

(34)

(30)

(3)

(6)

(1)

Total changes

(1,143)

(605)

(319)

(90)

(95)

(34)

 

 

 

 

 

 

 

Balance at December 31, 2007

 

 

 

 

 

Cost of acquisition

6,636

1,597

4,194

616

181

48

Accumulated depreciation/impairment

(4,433)

(823)

(3,100)

(471)

(39)

 

 

 

 

 

 

 

Carrying value

2,203

774

1,094

145

181

9

 

 

 

 

 

 

 

Changes in carrying value

 

 

 

 

 

 

Acquisitions through business combinations2

1,400

569

683

75

72

1

Divestments

(37)

(21)

(9)

(6)

(1)

Capital expenditures

534

102

357

58

17

Transfer between categories

(5)

14

(11)

2

Depreciation

(453)

(81)

(320)

(51)

(1)

Impairment

(134)

(67)

(56)

(5)

(3)

(3)

Changes in exchange rates

(156)

(55)

(57)

(33)

(11)

Total changes

1,154

463

600

24

69

(2)

 

 

 

 

 

 

 

Balance at December 31, 2008

 

 

 

 

 

Cost of acquisition

7,920

2,146

4,875

627

250

22

Accumulated depreciation/impairment

(4,563)

(909)

(3,181)

(458)

(15)

 

 

 

 

 

 

 

Carrying value

3,357

1,237

1,694

169

250

7

In 2008, impairment charges were recognized for an amount of €134 million (2007: €3 million), while no impairment charges have been reversed (2007: €7 million). The impairment charges were recognized in cost of sales. The impairment charges relate to restructuring activities in, among others Germany, and divestment activities in the UK.

The carrying value of property, plant and equipment financed by hire purchase and leasing and not legally owned by the company was €17 million (2007: €15 million) and comprised of €10 million to buildings and land, €3 million to plant equipment and machinery and €4 million to other equipment.

Purchase commitments for property, plant and equipment totaled €92 million (2007: €46 million). At December 2008 and 2007, no items of property, plant and equipment were registrered as security for bank loans.

Depreciation per cost category

Download XLS

 

 

In € millions

 

 

2008

 

 

Cost of sales

(307)

Selling expenses

(58)

General and administrative expenses

(50)

Research and development expenses

(14)

Other operating income/(expenses)

(24)

 

 

Total

(453)

Keyword Search
Copyright © 2009 Akzo Nobel N.V.